COVID Vaccine Postmarket Monitoring Will Depend On Which Adverse Events US FDA Wants To Watch

US FDA has the unenviable task of picking the most important adverse events to track once coronavirus vaccinations begin; CDC's list will need to be winnowed to 10-20 to make the surveillance feasible, and which AEs make the cut may be informed by the vaccine trials, as well as clinical experience with COVID infections.

Data monitoring (Titima Ongkantong/Shutterstock.com)
Those who receive a vaccine after approval will be alerted electronically to get their second dose, as well as report adverse events. • Source: Shutterstock

The US Food and Drug Administration has the unenviable task of picking the most important adverse events to track once coronavirus vaccination begins.

Agency officials expect to monitor adverse event reports in near real-time once a coronavirus vaccine becomes available. Data is expected...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet